2007.09.11 - IMCL
Pre-market:
IMCL - +27% gap a pre-marketben... jó hír a részvénynek és jó hír az embereknek......
"ImClone Systems Incorporated (NASDAQ:IMCL) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that a Phase III study of ERBITUX(R) (Cetuximab) in combination with platinum-based chemotherapy (vinorelbine plus cisplatin) met its primary endpoint of increasing overall survival compared with chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC). This large, randomized multi-national study, known as FLEX (First-Line Treatment for Patients with Epidermal growth factor inhibitor (EGFR)-EXpressing Advanced NSCLC) was conducted by Merck KGaA, Darmstadt, Germany and enrolled patients with Stage IIIB or Stage IV NSCLC who had not previously received chemotherapy."
Market open:Az IMCL lefelé indul, ami nem túl jó jel...
Viszont van esély a visszapattanásra....
A napi max egyben kétéves max. is. Áttörése belépési pont lehet...
Közeledünk...
Ez volt mára a tőzsde.
Market closed
Nincsenek megjegyzések:
Megjegyzés küldése